PT - JOURNAL ARTICLE AU - Vislay, Rebecca L. AU - Martin, Brandon S. AU - Olmos-Serrano, Jose Luis AU - Kratovac, Sebila AU - Nelson, David L. AU - Corbin, Joshua G. AU - Huntsman, Molly M. TI - Homeostatic Responses Fail to Correct Defective Amygdala Inhibitory Circuit Maturation in Fragile X Syndrome AID - 10.1523/JNEUROSCI.2764-12.2013 DP - 2013 Apr 24 TA - The Journal of Neuroscience PG - 7548--7558 VI - 33 IP - 17 4099 - http://www.jneurosci.org/content/33/17/7548.short 4100 - http://www.jneurosci.org/content/33/17/7548.full SO - J. Neurosci.2013 Apr 24; 33 AB - Fragile X syndrome (FXS) is a debilitating neurodevelopmental disorder thought to arise from disrupted synaptic communication in several key brain regions, including the amygdala, a central processing center for information with emotional and social relevance. Recent studies reveal defects in both excitatory and inhibitory neurotransmission in mature amygdala circuits in Fmr1−/y mutants, the animal model of FXS. However, whether these defects are the result of altered synaptic development or simply faulty mature circuits remains unknown. Using a combination of electrophysiological and genetic approaches, we show the development of both presynaptic and postsynaptic components of inhibitory neurotransmission in the FXS amygdala is dynamically altered during critical stages of neural circuit formation. Surprisingly, we observe that there is a homeostatic correction of defective inhibition, which, despite transiently restoring inhibitory synaptic efficacy to levels at or beyond those of control, ultimately fails to be maintained. Using inhibitory interneuron-specific conditional knock-out and rescue mice, we further reveal that fragile X mental retardation protein function in amygdala inhibitory microcircuits can be segregated into distinct presynaptic and postsynaptic components. Collectively, these studies reveal a previously unrecognized complexity of disrupted neuronal development in FXS and therefore have direct implications for establishing novel temporal and region-specific targeted therapies to ameliorate core amygdala-based behavioral symptoms.